Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71.
LONDON — A U.K. commission on Thursday unveiled its recommendations for how the country should regulate artificial intelligence in medicine, as health authorities globally try to determine how to continuously review ever-changing products after they have been authorized instead of simply clearing them once for the market.
In its report, the commission sought to strike a balance between ensuring that the U.K. takes advantage of AI’s potential in medicine — the ability to review the millions of scans that are generated each year to track the eye health of patients with diabetes, for example — while prioritizing safety, tracking device performance over time, and treating patients equitably.
The 44 recommendations include some that would allow for the staged authorization of new AI models and others that would build a system for providers to report how tools are performing in their clinics — including when they malfunction or potentially inhibit patient care — as the models learn and adapt and perform differently depending on the setting.
To read the rest of this story subscribe to STAT+.
Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71.
Originally reported by STAT News.